Pfizer has officially closed on its $10 billion purchase of obesity drug maker Metsera. So what does everyone think of the ...

Pfizer beats Q3 estimates, raises FY guidance, acquires Metsera for obesity drugs, and offers a 7% yield. Read here for an ...

Pfizer on Thursday closed its up to $10 billion acquisition of Metsera after winning shareholder approval, gaining a foothold ...

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ: MTSR), a ...

Shares of Metsera fell over 15% in premarket trading on Monday, after the weight-loss drug developer accepted a sweetened ...

Metsera said it has struck a revised merger agreement with Pfizer that values the company at up to $86.25 per share in cash.

Pfizer said on Thursday it completed an acquisition worth up to $10 billion of biotech firm Metsera after winning shareholder ...

Pfizer's agreement to buy Metsera just adds to the 83 healthcare deals counted by Goldman Sachs that were above $100 million ...

(Reuters) -Metsera shareholders on Thursday approved Pfizer's takeover offer worth up to $10 billion, as per preliminary ...

Pfizer eventually increased its offer. The company is now set to acquire Metsera in a deal worth up to $10 billion, including ...

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, ...